Celebrex (celecoxib) is now approved for a hereditary form of colorectal cancer

Celebrex (celecoxib) is now approved for a hereditary form of colorectal cancer.

It's the first drug in Canada to receive this indication.

Celebrex will be used to help reduce the number of colorectal polyps in patients with familial adenomatous polyposis (FAP).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote